Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) shares dropped 3.3% on Wednesday . The stock traded as low as $0.3771 and last traded at $0.3870. Approximately 8,181 shares traded hands during mid-day trading, an increase of 5% from the average daily volume of 7,789 shares. The stock had previously closed at $0.40.
Defence Therapeutics Stock Performance
The stock’s 50-day moving average price is $0.44 and its 200-day moving average price is $0.51.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Articles
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
